Mean arterial pressure at 11+0 to 13+6 weeks in the prediction of preeclampsia

Hypertension

Volumn 51, Issue 4 PART 2 SUPPL., 2008, Pages 1027-1033

  Poon, Leona C Y ^a   Kametas, Nikos A ^a   Pandeva, Ivilina ^a   Valencia, Catalina ^a   Nicolaides, Kypros H ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

First trimester; Mean arterial pressure; Preeclampsia; Pregnancy; Screening

Indexed keywords

ACETYLSALICYLIC ACID; ANTIASTHMATIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIRETROVIRUS AGENT; ANTITHYROID AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; INSULIN; LITHIUM; STEROID; THYROXINE;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ETHNIC DIFFERENCE; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL HYPERTENSION; MEAN ARTERIAL PRESSURE; PREECLAMPSIA; PREGNANCY TERMINATION; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SMOKING HABIT; SPONTANEOUS ABORTION; SYSTOLIC BLOOD PRESSURE; THROMBOPHILIA;

ADOLESCENT; ADULT; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; MASS SCREENING; MIDDLE AGED; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; RISK FACTORS;

EID: 40849085498     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.104646     Document Type: Article

References (43)

1. World Health Organization. Make Every Mother and Child Count. World Health Report, 2005. Geneva, Switzerland: World Health Organization; 2005.
2. Lewis G, ed. Why Mothers Die 2000-2002: The Sixth Report of Confidential Enquiries Into Maternal Deaths in the United Kingdom. London, United Kingdom: RCOG Press; 2004.
3. American College of Obstetricians and Gynecologists Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin: diagnosis and management of pre-eclampsia and eclampsia: number 33, January 2002. Obstet Gynecol. 2002;99:159-167.
4. Villar J, Abdel-Aleem H, Merialdi M, Mathai M, Ali MM, Zavaleta N, Purwar M, Hofmeyr J, Nguyen TN, Campódonico L, Landoulsi S, Carroli G, Lindheimer M; World Health Organization Calcium Supplementation for the Prevention of Preeclampsia Trial Group. World Health Organization Calcium Supplementation for the Prevention of Preeclampsia Trial Group. Am J Obstet Gynecol. 2006;194:639-649.
5. Rumbold AR, Crowther CA, Haslam RR, Dekker GA, Robinson JS, ACTS Study Group. Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med. 2006;354:1796-1806.
6. Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH. Vitamins in Pre-eclampsia (VIP) Trial Consortium. Lancet. 2006;367:1145-1154.
7. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA, on behalf of the PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369:1791-1798.
8. National Collaborating Centre for Women's and Children's Health. Commissioned by the National Institute for Clinical Excellence. Antenatal Care Routine Care for the Healthy Pregnant Woman. Clinical Guideline. October 2003. United Kingdom: National Collaborating Centre for Women's and Children's Health; 2003.
9. Yu CK, Smith GCS, Papageorghiou AT, Cacho AM, Nicolaides KH. An integrated model for the prediction of pre-eclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am J Obstet Gynecol. 2005;193:429-436.
10. Fallis NE, Langford HG. Relation of second trimester blood pressure to toxemia of pregnancy in the primigravid patient. Am J Obstet Gynecol. 1963;87:123-125.
11. Page EW, Christianson R. The impact of mean arterial pressure in the middle trimester upon the outcome of pregnancy. Am J Obstet Gynecol. 1976;125:740-746.
12. Phelan JP. Enhanced prediction of pregnancy-induced hypertension by combining supine pressor test with mean arterial pressure of middle trimester. Am J Obstet Gynecol. 1977;129:397-400.
13. Quaas L, Robrecht D, Kaltenbach FJ. The mean arterial pressure versus roll-over test as predictors of hypertensions in pregnancy. In: Samour MB, Symonds EM, Zuspan FP, El-Tomi N, eds. Pregnancy Hypertension. Cairo, Egypt: Ain Shams University Press; 1982:145-149.
14. Öney T, Kaulhausen H. The value of the mean arterial blood pressure in the second trimester (MAP-2 value) as a predictor of pregnancy-induced hypertension and preeclampsia. A preliminary report. Clin Exp Hypertens B. 1983;2:211-216.
15. Moutquin JM, Rainville C, Giroux L, Raynauld P, Amyot G, Bilodeau R, Pelland N. A prospective study of blood pressure in pregnancy: prediction of preeclampsia. Am J Obstet Gynecol. 1985;151:191-196.
16. Marya RK, Rathee S, Mittal R. Evaluation of three clinical tests for predicting pregnancy-induced hypertension. Am J Obstet Gynecol. 1988;158:683-684.
17. Villar MA, Sibai BM. Clinical significance of elevated mean arterial blood pressure in second trimester and threshold increase in systolic or diastolic blood pressure during third trimester. Am J Obstet Gynecol. 1989;160:419-423.
18. Ales KL, Norton ME, Druzin ML. Early prediction of antepartum hypertension. Obstet Gynecol. 1989;73:928-933.
19. Conde-Agudelo A, Belizän JM, Lede R, Bergel EF. What does an elevated mean arterial pressure in the second half of pregnancy predict-gestational hypertension or preeclampsia? Am J Obstet Gynecol. 1993;169:509-514.
20. Miller RS, Rudra CB, Williams MA. First-trimester mean arterial pressure and risk of preeclampsia. Am J Hypertens. 2007;20:573-578.
21. Mion D, Pierin AM. How accurate are sphygmomanometers? J Hum Hypertens. 1998;12:245-248.
22. Markandu ND, Whitcher F, Arnold A, Carney C. The mercury sphygmomanometer should be abandoned before it is proscribed. J Hum Hypertens. 2000;14:31-36.
23. Reinders A, Cuckson AC, Lee JT, Shennan AH. An accurate automated blood pressure device for use in pregnancy and pre-eclampsia: the Microlife 3BTO-A. BJOG. 2005;112:915-920.
24. Snijders RMJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Lancet. 1998;351:343-346.
25. Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol. 2004;191:45-67.
26. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ; Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45:142-161.
27. National Heart Foundation of Australia. Hypertension management guide for doctors 2004. Available at: http://www.heartfoundation.org.au. Accessed April 1, 2006.
28. Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol. 1988;158:892-898.
29. Gardosi J, Francis A. Software program for the calculation of customized birth weight percentiles. Version 6.2, 2000-2007. Available at: http://www.gestation.net. Accessed May 14, 2007.
30. United Kingdom National Screening Committee. Antenatal screening service for Down syndrome in England: 2001. A report to the United Kingdom National Screening Committee. August 2002. Available at: http://www.nsc.nhs.uk. Accessed October 2, 2007.
31. Royston P, Thompson SG. Model-based screening by risk with application to Down's syndrome. Stats in Med. 1992;11:257-268.
32. Rosenthal T, Oparil S. Hypertension in women. J Hum Hypertens. 2000;14:691-704.
33. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and blood pressure. JAMA. 1978;240:1607-1610.
34. Penney DG, Howley JW. Is there a connection between carbon monoxide exposure and hypertension? Environ Health Perspect. 1991;95:191-198.
35. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330:565-572.
36. Sibai BM, El-Nazer A, Gonzalez-Ruiz A. Severe preeclampsia-eclampsia in young gravid women: subsequent pregnancy outcome and remote prognosis. Am J Obstet Gynecol. 1986;155:1011-1016.
37. Manten GT, Sikkema MJ, Voorbij HA, Visser GH, Bruinse HW, Franx A. Risk factors for cardiovascular disease in women with a history of pregnancy complicated by preeclampsia or intrauterine growth restriction. Hypertens Pregnancy. 2007;26:39-50.
38. Eskenazi B, Fenster L, Sidney S. A multivariate analysis of risk factors for preeclampsia. JAMA. 1991;266:237-241.
39. Moldenhauer JS, Stanek J, Warshak C, Khoury J, Sibai B. The frequency and severity of placental findings in women with pre-eclampsia are gestational age dependent. Am J Obstet Gynecol. 2003;189:1173-1177.
40. Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD. Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. BJOG. 2006;113:580-589.
41. Plasencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH. Uterine artery Doppler at 11+0 to 13+6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2007;30:742-749.
42. Bosio PM, McKenna PJ, Conroy R, O'Herlihy C. Maternal central hemodynamics in hypertensive disorders or pregnancy. Obstet Gynecol. 1999;94:978-984.
43. D'Anna R, Baviera G, Corrado F, Giordano D, De Vivo A, Nicocia G, Di Benedetto A. Adiponectin and insulin resistance in early- and late-onset pre-eclampsia. BJOG. 2006;113:1264-1269.